Medical School · Year 3 · Family Medicine · includes a quiz and discussion video

Seminar 11: Women's Health in Family Medicine

Family Medicine Clerkship

Learning Objectives

By the end of this seminar, students will be able to:

1. Provide comprehensive contraceptive counseling using tiered effectiveness and the US Medical Eligibility Criteria
2. Evaluate and manage abnormal uterine bleeding using the PALM-COEIN classification system
3. Screen for and manage common gynecological conditions including vaginitis and cervical dysplasia
4. Address menopausal symptoms and apply evidence-based hormone therapy decision-making
5. Screen for intimate partner violence using validated tools and respond appropriately to disclosure
6. Integrate age-appropriate preventive care across the lifespan during the well-woman visit

Seminar Outline

Section 1: Contraception Counseling

Contraceptive methods are organized into tiers based on typical-use effectiveness, providing a framework for patient counseling. The most effective tier, with greater than ninety-nine percent efficacy, includes the intrauterine device, the subdermal implant, and surgical sterilization, all of which function independently of user adherence. The second tier includes injectable medroxyprogesterone acetate, the combined oral contraceptive pill, the transdermal patch, and the vaginal ring, which achieve ninety-one to ninety-nine percent effectiveness with typical use but are highly dependent on consistent and correct utilization. Barrier methods including male and female condoms, the diaphragm, and withdrawal offer moderate effectiveness ranging from seventy-six to eighty-eight percent. The least effective methods, including spermicide alone and fertility awareness-based methods, provide seventy-two to seventy-six percent typical-use effectiveness. Counseling should present all options to allow informed shared decision-making while emphasizing the superior effectiveness of long-acting methods.

Long-acting reversible contraception, commonly referred to as LARC, encompasses the intrauterine devices and the subdermal etonogestrel implant and represents the most effective reversible contraceptive option available. The copper intrauterine device provides non-hormonal contraception for up to ten years by creating a spermicidal intrauterine environment, though it may increase menstrual flow and cramping. Hormonal intrauterine devices releasing levonorgestrel are available in formulations lasting three to seven years depending on the specific product, and they commonly reduce menstrual bleeding, making them therapeutic for women with heavy menstrual bleeding. The subdermal implant, inserted in the upper arm, provides three years of progestin-only contraception with the most common side effect being irregular menstrual bleeding. Importantly, LARC methods can be offered to women of any age and parity, including nulliparous women and adolescents, as professional guidelines from the American College of Obstetricians and Gynecologists have endorsed LARC as a first-line option for all women.

Hormonal contraceptive methods beyond LARC include combined estrogen-progestin and progestin-only formulations delivered through various routes. The combined oral contraceptive pill is the most commonly used method, requiring daily ingestion, and provides additional benefits including regulation of menstrual cycles, reduction of acne, and decreased risk of ovarian and endometrial cancer. The progestin-only pill must be taken at the same time each day to maintain efficacy and is appropriate for women with contraindications to estrogen. The transdermal patch is applied weekly and delivers higher systemic estrogen levels than oral formulations, which may slightly increase the risk of venous thromboembolism. The vaginal ring is inserted monthly and provides stable hormone levels with a favorable bleeding profile. Injectable depot medroxyprogesterone acetate is administered every three months and is highly effective but is associated with weight gain and reversible bone mineral density loss with prolonged use.

Identifying contraindications to estrogen-containing methods is essential for safe prescribing, and the US Medical Eligibility Criteria provide a comprehensive framework for this assessment. Migraine with aura is an absolute contraindication to combined hormonal contraception due to the elevated risk of ischemic stroke. Women over age thirty-five who smoke are at substantially increased risk of venous thromboembolism and myocardial infarction with estrogen use. A personal history of venous thromboembolism, pulmonary embolism, or known thrombophilia precludes estrogen use. Current or prior hormone-receptor-positive breast cancer is a contraindication because estrogen may stimulate tumor growth. Severe uncontrolled hypertension with systolic pressure of one hundred sixty or greater or diastolic pressure of one hundred or greater represents an unacceptable cardiovascular risk with estrogen. For women with these contraindications, progestin-only methods including the hormonal IUD, implant, progestin-only pill, and injectable provide safe and effective alternatives.

<image>Panel A: Tiered effectiveness chart showing typical-use failure rates for all contraceptive methods arranged from most effective (IUD, implant, sterilization) to least effective (spermicide, fertility awareness), with visual comparison of failure rates per one hundred women per year. Panel B: Illustrations of LARC devices including the copper IUD, hormonal IUD, and subdermal implant with diagrams showing placement technique and mechanism of action. Panel C: Comparison of combined hormonal methods showing the oral contraceptive pill, transdermal patch, and vaginal ring with their administration schedules, estrogen exposure levels, and non-contraceptive benefits. Panel D: Flowchart for evaluating estrogen contraindications using US MEC criteria including migraine with aura, smoking over age thirty-five, VTE history, breast cancer, and severe hypertension, with alternative progestin-only options for each scenario.</image>

Section 2: Abnormal Uterine Bleeding

The PALM-COEIN classification system provides a standardized approach to categorizing the causes of abnormal uterine bleeding in reproductive-age women. The PALM component represents structural causes identifiable on imaging or histopathology: polyps, which are localized endometrial overgrowths; adenomyosis, in which endometrial glands invade the myometrium; leiomyomas (fibroids), which are benign smooth muscle tumors classified by their relationship to the uterine cavity; and malignancy or hyperplasia of the endometrium. The COEIN component represents non-structural causes: coagulopathy, which includes von Willebrand disease and other inherited bleeding disorders; ovulatory dysfunction, most commonly due to polycystic ovary syndrome or hypothalamic dysfunction; endometrial causes related to local alterations in hemostasis; iatrogenic factors including hormonal contraceptives and anticoagulant medications; and causes not yet classified. This systematic framework ensures comprehensive evaluation and prevents premature diagnostic closure.

Evaluation of abnormal uterine bleeding begins with a thorough history characterizing the bleeding pattern, volume, and associated symptoms. Laboratory assessment includes a complete blood count to evaluate for anemia, a urine or serum pregnancy test to exclude pregnancy-related causes, and thyroid-stimulating hormone to identify thyroid dysfunction. Coagulation studies should be considered in women with heavy menstrual bleeding since menarche, as up to twenty percent may have an underlying bleeding disorder, most commonly von Willebrand disease. Pelvic ultrasonography, preferably transvaginal, is the first-line imaging modality to evaluate for structural abnormalities including fibroids, polyps, and adenomyosis. Endometrial biopsy is indicated in women aged forty-five and older with abnormal bleeding, or in younger women with risk factors for endometrial cancer including obesity, chronic anovulation, tamoxifen use, or unopposed estrogen exposure.

Treatment of abnormal uterine bleeding is directed at the underlying cause whenever possible. Ovulatory dysfunction, the most common cause in reproductive-age women, is managed with hormonal therapy to regulate cycles and protect the endometrium. Uterine fibroids may be managed medically with hormonal agents to control bleeding or surgically with myomectomy or hysterectomy depending on size, symptoms, and reproductive goals. Endometrial polyps are typically removed via hysteroscopic polypectomy, which is both diagnostic and therapeutic. Coagulopathy-related bleeding requires hematology consultation for specific factor replacement or other targeted therapies. Endometrial hyperplasia without atypia may be treated with progestin therapy, while hyperplasia with atypia or endometrial malignancy requires gynecologic oncology referral.

Medical management options for heavy menstrual bleeding offer effective alternatives to surgical intervention. Nonsteroidal anti-inflammatory drugs reduce menstrual blood loss by twenty-five to fifty percent through inhibition of prostaglandin synthesis and are most effective when started at the onset of menses. Tranexamic acid, an antifibrinolytic agent, reduces bleeding by approximately forty percent and is taken only during the days of heaviest flow. Combined oral contraceptive pills regulate cycles and reduce endometrial proliferation. The levonorgestrel intrauterine device is the most effective medical therapy for heavy menstrual bleeding, reducing flow by more than ninety percent and serving as an alternative to hysterectomy. Gonadotropin-releasing hormone agonists induce a temporary medical menopause and are used short-term to shrink fibroids preoperatively or as a bridge to menopause, but their use is limited by hypoestrogenic side effects including bone loss.

<image>Panel A: Diagram of the PALM-COEIN classification with illustrations of structural causes (polyp, adenomyosis, leiomyoma, malignancy) shown on uterine cross-sections and non-structural causes listed with key diagnostic features. Panel B: Evaluation algorithm for abnormal uterine bleeding showing sequential steps from history and physical examination through laboratory testing, imaging, and endometrial biopsy with age-specific and risk-based indications. Panel C: Treatment decision tree organized by underlying cause showing hormonal management for ovulatory dysfunction, surgical options for fibroids and polyps, hematology referral for coagulopathy, and oncology referral for malignancy. Panel D: Comparison of medical therapies for heavy menstrual bleeding showing NSAIDs, tranexamic acid, combined OCP, levonorgestrel IUD, and GnRH agonists with their mechanisms, expected blood loss reduction, and duration of use.</image>

Section 3: Dysmenorrhea

Primary dysmenorrhea is defined as painful menstruation in the absence of identifiable pelvic pathology and is the most common gynecologic complaint among adolescents and young women. It typically develops within one to two years of menarche, coinciding with the establishment of regular ovulatory cycles, as prostaglandin-mediated uterine contractions require the progesterone-primed endometrium of an ovulatory cycle. The pathophysiology centers on excessive production of prostaglandin F2-alpha by the secretory endometrium during menstruation, which causes intense myometrial contractions, tissue ischemia, and sensitization of pain nerve endings. Symptoms characteristically begin within hours of the onset of menstrual flow and last one to three days, with crampy suprapubic pain that may radiate to the back and thighs. First-line treatment includes nonsteroidal anti-inflammatory drugs, which directly inhibit prostaglandin synthesis and are most effective when initiated at or just before the onset of menses, and hormonal contraception, which reduces endometrial prostaglandin production by suppressing ovulation and thinning the endometrial lining.

Secondary dysmenorrhea refers to menstrual pain caused by an underlying pelvic pathologic condition and should be suspected when dysmenorrhea develops after years of previously painless periods, when pain worsens progressively, or when it fails to respond to standard therapy. The most common causes include endometriosis, adenomyosis, uterine fibroids, and pelvic inflammatory disease. Red flag features that suggest secondary dysmenorrhea include onset in the third decade or later, pain that begins before menstrual flow and extends beyond its cessation, dyspareunia, abnormal bleeding patterns, and associated gastrointestinal or urinary symptoms. Evaluation includes a thorough pelvic examination, which may reveal uterosacral nodularity or a fixed retroverted uterus suggestive of endometriosis, and pelvic ultrasonography to assess for fibroids, adenomyosis, and ovarian endometriomas. Diagnostic laparoscopy remains the gold standard for definitive diagnosis of endometriosis, though empiric treatment is often initiated based on clinical suspicion.

Endometriosis is a chronic estrogen-dependent condition in which endometrial-like tissue implants outside the uterine cavity, most commonly on the pelvic peritoneum, ovaries, and rectovaginal septum. The classic symptom triad consists of progressive dysmenorrhea, dyspareunia (painful intercourse), and infertility, though presentations vary widely and severity of symptoms does not correlate with the extent of disease. Endometriosis affects approximately ten percent of reproductive-age women and represents a significant cause of chronic pelvic pain and subfertility. Medical treatment aims to suppress the growth of endometriotic implants through hormonal manipulation, including continuous combined oral contraceptive pills to eliminate menstruation, progestins such as norethindrone acetate or the levonorgestrel IUD, and gonadotropin-releasing hormone agonists for refractory cases. Surgical treatment via laparoscopy with excision or ablation of endometriotic implants is indicated when medical therapy fails, when fertility is desired, or when an endometrioma requires excision.

Premenstrual syndrome and premenstrual dysphoric disorder represent a spectrum of cyclical physical and emotional symptoms occurring during the luteal phase of the menstrual cycle. Premenstrual syndrome encompasses mild to moderate symptoms including bloating, breast tenderness, irritability, and mood lability that do not significantly impair daily functioning. Premenstrual dysphoric disorder is a more severe condition characterized by prominent mood symptoms including marked depressive mood, anxiety, affective lability, and irritability that cause significant functional impairment in work, social activities, or relationships. Diagnosis requires prospective documentation of symptoms over at least two consecutive menstrual cycles, with symptoms confined to the luteal phase and resolving within a few days of menses onset. First-line treatment for PMDD includes selective serotonin reuptake inhibitors, which can be administered continuously or only during the luteal phase with equivalent efficacy, combined oral contraceptive pills with drospirenone, and lifestyle modifications including regular aerobic exercise, stress management, and dietary changes such as reducing caffeine, alcohol, and sodium intake.

<image>Panel A: Pathophysiology diagram of primary dysmenorrhea showing prostaglandin F2-alpha production from the secretory endometrium, resulting myometrial contractions and ischemia, with corresponding pain distribution pattern on a body diagram and treatment algorithm with NSAIDs and hormonal contraception. Panel B: Comparison table of primary versus secondary dysmenorrhea features including age of onset, pain characteristics, response to therapy, and associated symptoms, with a list of secondary causes and corresponding red flags. Panel C: Anatomic diagram showing common sites of endometriotic implants on the pelvic peritoneum, ovaries, uterosacral ligaments, and rectovaginal septum, with laparoscopic photographs of implant appearances and treatment algorithm progressing from medical to surgical management. Panel D: Diagnostic criteria and symptom timeline for premenstrual dysphoric disorder showing luteal-phase symptom onset and menstrual-phase resolution across two consecutive cycles, with treatment options including continuous versus luteal-phase SSRI dosing and hormonal approaches.</image>

Section 4: Vaginitis

The three most common causes of infectious vaginitis are bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis, each with distinctive clinical features that guide diagnosis and treatment. Bacterial vaginosis produces a thin, grayish-white discharge with a characteristic fishy odor, particularly noticeable after intercourse or alkaline exposure, and vaginal pH is elevated above 4.5. Vulvovaginal candidiasis presents with a thick, white, cottage cheese-like discharge accompanied by intense vulvar pruritus and erythema, with a normal vaginal pH below 4.5. Trichomoniasis manifests as a profuse yellow-green, frothy discharge with vaginal erythema and a strawberry cervix appearance on examination, also with elevated pH above 4.5. Distinguishing among these entities through clinical features, office-based testing, and point-of-care diagnostics is an essential primary care skill that allows prompt initiation of appropriate treatment.

Bacterial vaginosis is not a true infection but rather a polymicrobial condition resulting from a shift in the vaginal microbiome away from the normal lactobacillus-dominant flora toward a mixed anaerobic population including Gardnerella vaginalis, Atopobium vaginae, and Prevotella species. Diagnosis is typically made using the Amsel criteria, which require three of the following four findings: characteristic thin homogeneous discharge, vaginal pH greater than 4.5, positive whiff test with release of fishy amine odor upon addition of potassium hydroxide, and the presence of clue cells on wet mount microscopy, which are vaginal epithelial cells studded with adherent bacteria obscuring the cell borders. Treatment consists of oral metronidazole five hundred milligrams twice daily for seven days, intravaginal metronidazole gel, or intravaginal clindamycin cream. Recurrence is common, affecting approximately fifty percent of women within twelve months, and may necessitate extended or suppressive therapy regimens.

Vulvovaginal candidiasis is classified as uncomplicated or complicated, with treatment differing accordingly. Uncomplicated candidiasis, defined as sporadic, mild-to-moderate infection caused by Candida albicans in an immunocompetent host, responds to a single oral dose of fluconazole one hundred fifty milligrams or a short course of intravaginal azole therapy for one to three days. Complicated candidiasis includes recurrent infection (four or more episodes per year), severe symptoms, non-albicans species such as Candida glabrata, and infection in immunocompromised or diabetic patients. Recurrent vulvovaginal candidiasis is managed with an induction course of fluconazole followed by weekly maintenance therapy for six months. Non-albicans species may be resistant to standard azole therapy and may require intravaginal boric acid capsules or topical amphotericin B. Patient counseling should address modifiable risk factors including antibiotic use, poorly controlled diabetes, and immunosuppression.

Trichomoniasis is the most common non-viral sexually transmitted infection worldwide, caused by the protozoan parasite Trichomonas vaginalis. Because it is sexually transmitted, partner treatment is mandatory to prevent reinfection, and patients should abstain from intercourse until both partners have completed therapy and are asymptomatic. The standard treatment is oral metronidazole, either as a single two-gram dose or five hundred milligrams twice daily for seven days, with the seven-day regimen recommended for HIV-positive women due to higher treatment failure rates with single-dose therapy. A test of cure is recommended at three months for all women treated for trichomoniasis due to the high reinfection rate, which may exceed seventeen percent within three months. Screening for trichomoniasis should be performed in women with HIV, those presenting with vaginitis symptoms, and women at increased risk for sexually transmitted infections, as many infections are asymptomatic but carry consequences including preterm birth and increased HIV acquisition risk.

<image>Panel A: Side-by-side comparison of the three common vaginitis causes showing characteristic discharge appearance, pH values, and microscopic findings for bacterial vaginosis (clue cells), candidiasis (pseudohyphae and budding yeast), and trichomoniasis (motile trichomonads). Panel B: Amsel criteria diagnostic flowchart for bacterial vaginosis with photographs of thin homogeneous discharge, positive whiff test technique, and microscopic image of clue cells compared to normal epithelial cells. Panel C: Classification algorithm for vulvovaginal candidiasis distinguishing uncomplicated from complicated infection with treatment pathways including single-dose fluconazole, extended courses, and maintenance therapy for recurrent disease. Panel D: Trichomoniasis management algorithm showing single-dose versus seven-day metronidazole regimens, mandatory partner treatment, test-of-cure timing, and screening recommendations for high-risk populations.</image>

Section 5: Cervical Cancer Screening

Current cervical cancer screening guidelines represent a significant evolution from earlier annual Pap smear recommendations and are based on the understanding that cervical cancer develops slowly through a well-characterized progression from HPV infection to precancerous dysplasia to invasive carcinoma. Screening is not recommended before age twenty-one regardless of sexual activity, as cervical cancer is extremely rare in this age group and transient HPV infections are common and typically clear spontaneously. For women aged twenty-one to twenty-nine, cervical cytology alone (Pap smear) every three years is recommended. Women aged thirty to sixty-five have three acceptable screening strategies: cervical cytology alone every three years, co-testing with cytology and high-risk HPV testing every five years, or primary HPV testing alone every five years. Screening may be discontinued after age sixty-five in women with adequate prior negative screening results, and in women who have undergone hysterectomy with removal of the cervix for benign indications and have no history of cervical intraepithelial neoplasia grade two or higher.

HPV testing has assumed an increasingly central role in cervical cancer screening due to its higher sensitivity for detecting high-grade precancerous lesions compared to cytology alone. Primary HPV testing has been approved as a stand-alone screening option for women aged twenty-five and older, detecting fourteen high-risk HPV types with genotyping for types sixteen and eighteen, which together account for approximately seventy percent of cervical cancers. Co-testing combines HPV testing with cytology and offers the advantage of high sensitivity with high negative predictive value, allowing safe extension of the screening interval to five years. Reflex HPV testing is performed when a Pap smear shows atypical squamous cells of undetermined significance (ASCUS), with a positive HPV result triggering colposcopy and a negative result allowing return to routine screening. HPV genotyping for types sixteen and eighteen provides additional risk stratification, as these types carry the highest risk of progression to high-grade dysplasia and cancer.

Management of abnormal cervical cancer screening results follows evidence-based algorithms that balance the risk of missed precancerous lesions against the morbidity of unnecessary procedures. ASCUS with negative HPV testing is managed with a return to routine screening, as the risk of underlying high-grade disease is very low. ASCUS with positive HPV testing or low-grade squamous intraepithelial lesion (LSIL) warrants colposcopy with biopsy of any visible lesions. High-grade squamous intraepithelial lesion (HSIL) requires colposcopy and frequently leads to an excisional procedure such as loop electrosurgical excision procedure (LEEP). Atypical squamous cells cannot exclude high-grade (ASC-H) also requires colposcopy due to the significant probability of underlying high-grade disease. Management decisions are increasingly guided by risk-based algorithms that integrate cytology results, HPV status, and prior screening history to determine whether surveillance, colposcopy, or treatment is indicated.

HPV vaccination represents the most effective primary prevention strategy against cervical cancer and has dramatically altered the landscape of HPV-related disease since its introduction. The current nonavalent vaccine provides protection against HPV types six, eleven, sixteen, eighteen, thirty-one, thirty-three, forty-five, fifty-two, and fifty-eight, covering the types responsible for approximately ninety percent of cervical cancers and ninety percent of genital warts. The recommended schedule is two doses given six to twelve months apart for individuals initiating vaccination before age fifteen, and three doses at zero, one to two, and six months for those beginning at age fifteen or older. Routine vaccination is recommended at age eleven to twelve but may be given as early as age nine. Catch-up vaccination is recommended through age twenty-six, and shared clinical decision-making is appropriate for adults aged twenty-seven to forty-five who have not been adequately vaccinated, though the benefit diminishes with increasing age and prior HPV exposure.

<image>Panel A: Timeline of cervical cancer screening recommendations by age group showing no screening before twenty-one, cytology alone every three years for ages twenty-one to twenty-nine, and three acceptable strategies (cytology, co-testing, or primary HPV testing) for ages thirty to sixty-five with stopping criteria. Panel B: Comparison of HPV testing strategies showing primary HPV testing, co-testing, and reflex HPV testing with their sensitivity, specificity, and recommended screening intervals, highlighting HPV types sixteen and eighteen genotyping. Panel C: Management algorithm for abnormal cervical screening results showing pathways from ASCUS (HPV negative versus positive), LSIL, HSIL, and ASC-H through colposcopy, biopsy, and treatment including LEEP. Panel D: HPV vaccination schedule showing two-dose and three-dose regimens by age, recommended ages for routine and catch-up vaccination, types covered by the nonavalent vaccine, and expected cancer prevention impact.</image>

Section 6: Breast Health

Breast cancer screening recommendations vary among major guideline organizations, reflecting differing interpretations of the balance between early detection benefits and screening harms. The United States Preventive Services Task Force recommends biennial screening mammography for women aged fifty to seventy-four, with the decision to begin screening in the forty to forty-nine age group left to individual assessment based on patient values regarding potential benefits and harms. The American Cancer Society recommends annual mammography beginning at age forty-five, transitioning to biennial screening at age fifty-five. Shared decision-making is the common thread across all guidelines, requiring clinicians to discuss the mortality reduction achieved through screening, estimated at approximately twenty percent for women screened biennially, alongside the potential harms including false-positive results requiring additional imaging or biopsy, overdiagnosis of indolent cancers, and the anxiety associated with callbacks. Women at high risk due to BRCA mutations, prior chest radiation, or strong family history should begin screening earlier and may benefit from supplemental breast MRI.

Evaluation of a breast mass follows an age-based approach that optimizes diagnostic accuracy. In women under age thirty, ultrasonography is the preferred initial imaging modality because the dense breast tissue in younger women limits mammographic sensitivity, and the low pretest probability of malignancy reduces the benefit of radiation exposure. In women aged thirty and older, diagnostic mammography is the first-line study, often supplemented by targeted ultrasound for further characterization. Regardless of imaging findings, any clinically suspicious mass requires tissue diagnosis through biopsy, as imaging alone cannot definitively exclude malignancy. The triple test, which combines clinical examination, imaging, and tissue pathology, provides the highest diagnostic accuracy and is the standard approach for palpable breast masses, with concordance among all three components providing greater than ninety-nine percent diagnostic accuracy.

Several benign breast conditions account for the majority of breast complaints encountered in primary care. Fibroadenomas are the most common benign breast tumors, presenting as firm, mobile, well-circumscribed, painless masses in women under thirty, and can be managed with observation once confirmed by core needle biopsy. Fibrocystic changes represent the most common cause of breast symptoms overall, manifesting as bilateral lumpy, tender breast tissue with symptoms that fluctuate with the menstrual cycle and typically peak in the premenstrual period. Simple breast cysts are fluid-filled structures that can be confirmed by ultrasound and, if symptomatic, aspirated for relief, with cytologic examination of the aspirated fluid. Mastalgia, or breast pain, is extremely common and is usually cyclical, related to hormonal fluctuations, and rarely indicative of malignancy, though evaluation with imaging is appropriate when pain is focal, persistent, or associated with a palpable abnormality.

Management of breast pain depends on its classification and severity. Cyclical mastalgia, which accounts for approximately two-thirds of breast pain complaints, is related to hormonal fluctuations and typically improves with reassurance that it does not signify cancer, a well-fitting supportive bra, and nonsteroidal anti-inflammatory drugs applied topically or taken orally. Dietary modifications including reduction of caffeine intake, though evidence is limited, may provide subjective improvement for some women. Non-cyclical breast pain requires investigation for underlying causes including musculoskeletal disorders such as costochondritis, which is a common mimic, as well as medication effects and, rarely, inflammatory breast conditions. For severe refractory cyclical mastalgia, danazol, a synthetic androgen, is the only FDA-approved medication but is limited by androgenic side effects, and its use has largely been supplanted by topical NSAIDs and evening primrose oil, though the latter lacks strong evidence of efficacy.

<image>Panel A: Comparison chart of breast cancer screening recommendations from USPSTF, ACS, and ACR showing recommended start age, screening frequency, supplemental MRI criteria, and stopping age, with shared decision-making elements highlighted. Panel B: Age-based evaluation algorithm for a breast mass showing ultrasound-first approach for women under thirty and mammography-first approach for women thirty and older, with biopsy pathways and the triple test components. Panel C: Ultrasound and clinical photographs of common benign breast conditions including fibroadenoma showing well-circumscribed hypoechoic mass, fibrocystic changes with cystic and solid components, simple cyst with anechoic fluid, and mammographic appearance of each. Panel D: Breast pain management algorithm distinguishing cyclical from non-cyclical mastalgia with treatment options including reassurance, supportive measures, NSAIDs, and evaluation for musculoskeletal mimics such as costochondritis.</image>

Section 7: Menopause

The menopausal transition encompasses distinct phases defined by reproductive hormonal changes. Perimenopause, or the menopausal transition, is characterized by fluctuating estrogen levels and irregular menstrual cycles, typically beginning in the mid-forties and lasting an average of four years. Menopause is defined retrospectively as the point at which twelve consecutive months have elapsed without menstrual bleeding, with the average age of natural menopause being fifty-one years. Premature menopause occurring before age forty, also termed premature ovarian insufficiency, warrants additional evaluation including karyotype and autoimmune markers, and carries long-term health implications including increased cardiovascular risk and accelerated bone loss that may warrant hormone replacement until the typical age of menopause. The diagnosis of menopause is clinical in women over age forty-five with typical symptoms and amenorrhea, and measurement of follicle-stimulating hormone is generally unnecessary in this population but may be helpful in younger women or those with prior hysterectomy.

Menopausal symptoms reflect the physiologic effects of estrogen withdrawal across multiple organ systems. Vasomotor symptoms, including hot flashes and night sweats, are the hallmark of menopause and affect up to eighty percent of women, with a median duration of seven years. Hot flashes consist of a sudden sensation of heat spreading over the upper body and face, often accompanied by flushing, diaphoresis, and palpitations, and can significantly disrupt sleep, work productivity, and quality of life. Genitourinary syndrome of menopause encompasses vaginal dryness, dyspareunia, vulvar irritation, and urinary symptoms including urgency and recurrent urinary tract infections, resulting from atrophy of estrogen-dependent urogenital tissues. Psychological symptoms including mood changes, irritability, difficulty concentrating, and sleep disturbance are common during the transition. Accelerated bone loss occurs in the first five to ten years following menopause due to estrogen withdrawal, increasing the risk of osteoporotic fractures.

Hormone therapy remains the most effective treatment for moderate-to-severe vasomotor symptoms and should be considered within the context of an individualized risk-benefit assessment. The timing hypothesis supports initiation of hormone therapy within ten years of menopause onset or before age sixty, when the cardiovascular risk profile is most favorable. Women without a uterus may use estrogen alone, while women with an intact uterus require combined estrogen-progestogen therapy to prevent estrogen-induced endometrial hyperplasia and cancer. The lowest effective dose should be prescribed, and therapy should be reassessed periodically, though there is no arbitrary mandatory duration limit. Transdermal estrogen formulations may confer a lower risk of venous thromboembolism compared to oral preparations, as they avoid first-pass hepatic metabolism and the resultant prothrombotic changes in coagulation factors. For women whose primary complaint is genitourinary syndrome of menopause, low-dose vaginal estrogen is highly effective, carries minimal systemic absorption, and does not require concomitant progestogen in most clinical scenarios.

Hormone therapy carries risks that must be weighed against benefits during the counseling process. The risk of venous thromboembolism is increased approximately twofold with oral hormone therapy, though transdermal formulations may mitigate this risk. Combined estrogen-progestogen therapy is associated with a small increase in breast cancer risk that becomes statistically significant after approximately three to five years of use, while estrogen-only therapy does not appear to increase breast cancer risk and may even be associated with a reduction. The risk of ischemic stroke is modestly increased with hormone therapy. Coronary heart disease risk may be increased when therapy is initiated in older women remote from menopause, underscoring the importance of the timing hypothesis. Absolute contraindications to systemic hormone therapy include a history of breast cancer, prior venous thromboembolism or pulmonary embolism, active liver disease, unexplained vaginal bleeding, and known coronary heart disease or prior stroke. Non-hormonal alternatives should be offered to women with these contraindications.

Non-hormonal options provide meaningful symptom relief for women who cannot or choose not to use hormone therapy. Among pharmacologic options, paroxetine at seven and a half milligrams is the only FDA-approved non-hormonal treatment for vasomotor symptoms, though other SSRIs and SNRIs including venlafaxine and escitalopram have also demonstrated efficacy in clinical trials. Gabapentin, particularly at bedtime dosing, reduces hot flash frequency and severity and may additionally improve sleep quality. Clonidine, an alpha-2 adrenergic agonist, provides modest hot flash reduction but is limited by side effects including dry mouth, dizziness, and constipation. For genitourinary syndrome of menopause, vaginal moisturizers applied regularly and lubricants used during intercourse provide symptomatic relief, and low-dose vaginal estrogen, which has minimal systemic absorption, may be appropriate even in some women with relative contraindications to systemic therapy after careful discussion. Ospemifene, a selective estrogen receptor modulator, is approved for dyspareunia due to vulvovaginal atrophy.

<image>Panel A: Timeline of the menopausal transition showing perimenopause, menopause, and postmenopause with corresponding hormonal changes in estrogen and FSH levels, menstrual pattern alterations, and average age ranges. Panel B: Body diagram illustrating menopausal symptoms across organ systems including vasomotor (hot flashes, night sweats), genitourinary (vaginal atrophy, urinary symptoms), psychological (mood changes, sleep disturbance), and skeletal (accelerated bone loss). Panel C: Hormone therapy decision algorithm incorporating the timing hypothesis, uterus status (estrogen alone versus combined therapy), route of administration (oral versus transdermal), dose optimization, and periodic reassessment schedule. Panel D: Comparison of non-hormonal options for vasomotor symptoms showing paroxetine, venlafaxine, gabapentin, and clonidine with their efficacy data, dosing, and side effect profiles, alongside vaginal management options for genitourinary syndrome.</image>

Section 8: Intimate Partner Violence

Screening for intimate partner violence is a critical component of comprehensive women's healthcare, as IPV affects approximately one in four women during their lifetime and has profound consequences for physical and mental health. The USPSTF recommends screening all women of reproductive age, and screening should be conducted at new patient visits, periodically during ongoing care, during pregnancy, and when clinical presentations raise concern. Validated screening instruments include HITS (Hurt, Insult, Threaten, Scream), HARK (Humiliation, Afraid, Rape, Kick), and STaT (Slapped, Threatened, and Thrown). The screening conversation must take place in a private setting with the patient alone, without partners, family members, or children present who might inhibit disclosure. Confidentiality should be explained and maintained, with clear communication about mandatory reporting requirements where applicable.

The approach to asking about intimate partner violence requires sensitivity, directness, and normalization to create a safe space for disclosure. Framing the conversation as routine practice reduces stigma and patient discomfort, using language such as "Because violence is so common and affects so many people's health, I ask all my patients about safety in their relationships." Direct questions should follow, such as "Has anyone ever physically hurt you or made you feel afraid?" and "Do you feel safe in your current relationship?" If the patient denies violence, the clinician should express openness to future discussion with a statement such as "If anything ever changes or if you want to talk about this in the future, I am here for you." The goal is not to elicit disclosure at every encounter but to establish trust and communicate that the healthcare setting is a safe environment for these conversations.

When a patient discloses intimate partner violence, the clinician's response must prioritize validation, safety assessment, and connection to resources. The first step is to believe the patient and express gratitude for their trust, using language such as "Thank you for telling me. I believe you, and this is not your fault." An immediate safety assessment follows, asking whether the patient feels safe going home and whether there is an escalation pattern or access to weapons. Documentation should be thorough, objective, and detailed, using the patient's own words when possible, and should include the nature, frequency, and severity of abuse, physical examination findings including photographs with consent, and safety plan elements. Resources should be provided, including the National Domestic Violence Hotline at one eight hundred seven nine nine seven two three three, local shelter information, and safety planning assistance. Critically, the clinician should not pressure the patient to leave the relationship, as leaving is the most dangerous period and the decision must rest with the patient when it is safe to do so.

Multiple clinical presentations should prompt the clinician to consider intimate partner violence as a contributing factor. Physical injuries that are inconsistent with the reported mechanism, particularly injuries in various stages of healing or in locations typically covered by clothing, are red flags. Delayed presentation for care, often with implausible explanations for the delay, may reflect a controlling partner. The presence of a partner who insists on being in the examination room, answers questions on the patient's behalf, or appears overtly controlling should raise suspicion. Chronic conditions commonly associated with IPV include chronic pain syndromes, irritable bowel syndrome, recurrent headaches, depression, anxiety, post-traumatic stress disorder, and substance use disorders. Frequent visits for vague or changing complaints may also represent a pattern of help-seeking behavior that warrants sensitive inquiry.

<image>Panel A: Infographic showing IPV prevalence statistics, health consequences across physical, mental, and reproductive health domains, and USPSTF screening recommendation with validated screening tools (HITS, HARK, STaT) and their questions. Panel B: Step-by-step communication guide for asking about IPV showing normalization statements, direct screening questions, and supportive closing statements with specific language examples for each step. Panel C: Disclosure response protocol showing validation statements, safety assessment questions, documentation requirements including body diagram for injury mapping, resource provision including National Hotline number, and safety planning elements. Panel D: Clinical presentation red flags for IPV including injury pattern photographs, psychological presentations, behavioral indicators such as a controlling partner, and chronic conditions commonly associated with intimate partner violence.</image>

Section 9: Preconception and Interconception Care

Preconception counseling optimizes maternal and fetal health by addressing modifiable risk factors before conception occurs. Folic acid supplementation at four hundred to eight hundred micrograms daily should begin at least one month before conception and continue through the first trimester to reduce the risk of neural tube defects, with higher doses of four milligrams daily recommended for women with a prior affected pregnancy, those taking antiepileptic medications, or those with diabetes. Chronic medical conditions including diabetes, hypertension, epilepsy, thyroid disease, and autoimmune disorders should be optimized before conception, as poorly controlled disease increases the risk of adverse pregnancy outcomes. A comprehensive medication review is essential to identify and discontinue or substitute teratogenic agents. Immunization status should be confirmed and updated, with particular attention to rubella and varicella immunity, as live vaccines must be administered at least one month before conception. Lifestyle counseling addresses tobacco cessation, alcohol avoidance, substance use, healthy weight achievement, and environmental exposures, while genetic carrier screening should be offered based on family history and ethnic background.

Several medication classes pose significant teratogenic risk and must be identified and addressed during preconception planning. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers cause renal dysgenesis and oligohydramnios and should be replaced with safer antihypertensives such as labetalol or nifedipine. Warfarin is associated with fetal warfarin syndrome including nasal hypoplasia and skeletal abnormalities and should be transitioned to low-molecular-weight heparin. Isotretinoin is one of the most potent known teratogens, causing severe craniofacial, cardiac, and central nervous system malformations, and must be discontinued with confirmation of pregnancy prevention. Valproic acid carries a dose-dependent risk of neural tube defects, cognitive impairment, and other malformations and should be replaced with alternative antiepileptic agents when possible. Methotrexate, statins, and certain antibiotics including tetracyclines and fluoroquinolones are additional medications requiring pregnancy planning. Documentation of the teratogen discussion, the plan for medication changes, and confirmation of contraception until safe substitution is complete is essential.

Interconception care refers to the healthcare provided between the end of one pregnancy and the beginning of the next, representing a critical window for health optimization. The recommended interpregnancy interval is eighteen to twenty-four months, as shorter intervals are associated with increased risks of preterm birth, low birth weight, and small-for-gestational-age infants. Complications from a prior pregnancy, including gestational diabetes, preeclampsia, preterm birth, and postpartum depression, should be addressed during this period, as many of these conditions carry implications for future pregnancies and long-term maternal health. Women with prior gestational diabetes should undergo glucose tolerance testing at six to twelve weeks postpartum and annually thereafter, as their lifetime risk of developing type 2 diabetes is approximately fifty percent. Effective contraception should be discussed and initiated in the postpartum period to allow adequate pregnancy spacing, with LARC methods being particularly appropriate given their effectiveness and the elimination of adherence requirements during the demanding postpartum period.

The initial evaluation of infertility falls within the scope of family medicine practice before referral to reproductive endocrinology. Infertility is defined as the inability to achieve clinical pregnancy after twelve months of regular unprotected intercourse in women under age thirty-five, or after six months in women aged thirty-five and older, reflecting the accelerated decline in fertility with advancing maternal age. The female evaluation includes assessment of ovulatory function through menstrual history, mid-luteal progesterone levels, or ovulation predictor kits; evaluation of tubal patency through hysterosalpingography; and assessment of the uterine cavity through ultrasonography or saline infusion sonography. The male evaluation centers on semen analysis, which should be obtained early in the workup given that male factor contributes to approximately forty to fifty percent of infertility cases. Basic laboratory testing including thyroid function, prolactin, and day-three FSH and estradiol levels provides additional information about ovarian reserve and hormonal status. Referral to a reproductive endocrinologist is appropriate once the initial evaluation is complete or when age or clinical circumstances suggest that prompt specialist evaluation is warranted.

<image>Panel A: Preconception counseling checklist organized by domain showing folic acid supplementation dosing, chronic disease optimization targets, medication review with teratogen screening, immunization assessment, lifestyle modifications, and genetic screening recommendations. Panel B: Visual reference of major teratogenic medications with their fetal effects including ACE inhibitors causing renal dysgenesis, warfarin causing skeletal abnormalities, isotretinoin causing craniofacial defects, and valproic acid causing neural tube defects, with recommended safe alternatives for each. Panel C: Interconception care timeline showing recommended interpregnancy interval, postpartum evaluation schedule for prior complications including glucose testing for gestational diabetes, mental health screening, and contraception initiation with emphasis on LARC methods. Panel D: Infertility evaluation algorithm showing the definition by age, parallel female evaluation (ovulation assessment, tubal patency, uterine cavity) and male evaluation (semen analysis), basic laboratory testing, and referral criteria for reproductive endocrinology.</image>

Section 10: Integrating Women's Preventive Care

The well-woman visit is a comprehensive encounter that extends beyond reproductive health to address the full spectrum of preventive care needs. Core components include age-appropriate screening tests such as cervical cytology and mammography performed according to guideline-recommended intervals, immunizations including HPV vaccine for eligible women, tetanus-diphtheria-pertussis booster, and annual influenza vaccination, and risk assessments for cardiovascular disease, cancer, and mental health conditions. Counseling should address contraceptive needs and reproductive life planning, healthy lifestyle behaviors including diet, physical activity, and substance avoidance, and safety concerns including intimate partner violence screening. The physical examination is tailored to the clinical context and may include breast examination, pelvic examination when indicated by symptoms or screening needs, and blood pressure measurement. This visit represents an important touchpoint for establishing rapport, identifying unrecognized conditions, and reinforcing the therapeutic relationship.

Preventive care priorities shift across the lifespan, requiring the clinician to adapt the approach to each patient's age and life stage. For adolescents, the focus centers on confidential care, contraceptive counseling, HPV vaccination, and screening for depression and substance use, with particular attention to creating a trusting clinical relationship. During the reproductive years, priorities include contraception management, preconception counseling when pregnancy is desired, sexually transmitted infection screening, and cervical cancer screening. The perimenopausal period requires attention to vasomotor symptom management, bone health assessment, and cardiovascular risk factor modification as estrogen's protective effects wane. In the postmenopausal years, osteoporosis screening with dual-energy X-ray absorptiometry, cardiovascular disease prevention, cancer screening with attention to appropriate cessation ages, and management of genitourinary syndrome of menopause become central concerns.

Special populations require thoughtful adaptation of standard preventive care approaches. LGBTQ-plus women may face barriers to care including discrimination, lack of provider knowledge, and assumptions about sexual behavior and screening needs, and clinicians should use inclusive language, affirming practices, and appropriate screening based on actual sexual behaviors and anatomy rather than identity alone. Women with disabilities may require physical accommodations such as accessible examination tables and modified equipment, as well as recognition that standard screening and prevention guidelines apply equally regardless of disability status. Survivors of sexual assault or other trauma benefit from trauma-informed care approaches that prioritize patient control, informed consent for each element of the examination, and sensitivity to the potential for re-traumatization during pelvic examinations. Women with limited economic resources may benefit from connection to Title X family planning clinics, community health centers, and programs that provide low-cost or free screening and contraception.

A comprehensive approach to women's health embraces principles that extend beyond disease-specific screening to address the whole person across the entire lifespan. This means recognizing that women's health encompasses far more than reproductive concerns, including cardiovascular disease, which is the leading cause of death in women, mental health conditions, musculoskeletal disorders, and autoimmune diseases that disproportionately affect women. Continuity of care across life transitions, from adolescence through the reproductive years, menopause, and beyond, allows the family physician to provide integrated, longitudinal care that responds to evolving health needs. Accessibility requires attention to reducing barriers including cost, transportation, childcare, language, and cultural factors that may prevent women from engaging with preventive services. Equity demands recognition and active mitigation of health disparities, including the persistent disparities in maternal mortality, cervical cancer mortality, and breast cancer mortality experienced by Black women and other historically marginalized populations.

<image>Panel A: Well-woman visit template showing organized components including screening tests by age, immunization assessment, risk factor evaluation, counseling topics, examination elements, and documentation requirements with recommended time allocation for each. Panel B: Lifespan preventive care timeline for women showing age-specific priorities from adolescence through postmenopause with color-coded domains for reproductive health, cancer screening, cardiovascular prevention, bone health, and mental health. Panel C: Clinical scenarios illustrating adapted care for special populations including LGBTQ-plus women with inclusive intake form examples, women with disabilities with accessible examination equipment, trauma survivors with trauma-informed examination techniques, and low-income women with resource navigation pathways. Panel D: Comprehensive women's health framework diagram showing interconnection of whole-person care, continuity across life stages, accessibility, and equity with specific action items for each principle and health outcomes data demonstrating persistent disparities.</image>

Summary

• LARC methods (IUD, implant) are the most effective reversible contraception and can be offered to women of any age or parity
• Estrogen-containing contraception is contraindicated in migraine with aura, smoking over age thirty-five, VTE history, and breast cancer
• Abnormal uterine bleeding is classified using PALM-COEIN, with endometrial biopsy indicated at age forty-five or older or with risk factors
• Bacterial vaginosis presents with gray fishy discharge, pH above 4.5, and clue cells on wet mount and is treated with metronidazole
• Cervical screening begins at age twenty-one with cytology every three years, and from age thirty to sixty-five offers cytology, co-testing, or HPV testing options
• Breast cancer screening with mammography is recommended biennially from age fifty to seventy-four by USPSTF, with individual decision-making for ages forty to forty-nine
• Menopause management centers on vasomotor symptoms, with hormone therapy being most effective when initiated within ten years of menopause or before age sixty
• Hormone therapy risks include VTE, breast cancer with combined therapy, and stroke, and is contraindicated with history of these conditions
• IPV screening should be performed for all women in a private setting with validated tools, responding to disclosure with belief, safety assessment, and resources
• Preconception care includes folic acid four hundred to eight hundred micrograms daily, teratogenic medication review, chronic disease optimization, and immunization updates

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown